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Cancer immunotherapy has emerged as a mainstream therapy option in the battle against
cancer. Pre-clinical data demonstrates the ability of immunotherapy to harness the immune
system to fight disseminated malignancy. Clinical translation has failed to recapitulate the
promising results of pre-clinical studies although there have been some successes. In this
review we explore some of the short-comings of cancer immunotherapy that have lim-
ited successful clinical translation. We will give special consideration to what we consider
the most formidable hurdle to successful cancer immunotherapy: tumor-induced immune
suppression and immune escape. We will discuss the need for antigen-specific immune
responses for successful immunotherapy but also consider the need for antigen speci-
ficity as an Achilles heel of immunotherapy given tumor heterogeneity, immune editing,
and antigen loss. Finally, we will discuss how combinatorial strategies may overcome some
of the pitfalls of antigen specificity and highlight recent studies from our lab which suggest
that the induction of antigen non-specific immune responses may also produce robust
anti-tumor effects and bypass the need for antigen specificity.
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INTRODUCTION
The allure of cancer immunotherapy as a potential magic bul-
let against cancer has intrigued researchers for over a century.
The rationale underlying anti-cancer immunotherapy stems from
the concept of immune surveillance first attributed to Erlich and
colleagues over a century ago (1). This concept, founded in the
idea that there is no evolutionary purpose to the tissue rejection
immune response, states that tissue rejection is actually a manifes-
tation of an immune surveillance mechanism that guards against
spontaneously arising tumors. If such a mechanism does exist then
it stands to reason that it can be re-invigorated and harnessed to
battle malignancy in cancer patients. This idea, in its simplest form,
is particularly attractive given that the immune system should be
able to identify and specifically eradicate malignant cells based on
the expression of abnormal antigens not expressed or present in
normal tissues (2).
Interest in this concept has waxed and waned over the past cen-
tury and during this time the major advances in cancer therapy
were focused on cytotoxic therapies and surgical excision. Despite
the continual advancement of the field, the inability to eradicate
malignancy once it has disseminated remains the greatest challenge
in cancer therapy. Over the past decade there has been a renais-
sance in cancer immunotherapy with a renewed belief by many
that harnessing the immune system may be a viable strategy for
successfully treating metastatic disease. This renaissance has pro-
duced a seemingly exponentially increasing number of pre-clinical
and clinical studies which are serving to translate this concept into
the mainstream arsenal of anti-cancer therapeutics. Numerous
strategies are being explored including augmentation of antigen-
presenting cells (APC) and immune effector cells, immunologic
stimulants such as cytokines and pathogen associated molecular
pattern (PAMP) receptor agonists, adoptive transfer of transgenic
immune cells, antibodies and molecules such as anti-CTLA-4 anti-
body or transforming growth factor (TGF)-beta antisense aimed at
reversing suppressive mechanisms, and numerous vaccines com-
prised of DNA, peptides, or autologous tumor cells [reviewed in
Ref. (3, 4)]. Two such therapies, sipuleucel-T, a pulsed dendritic cell
vaccine (5), and ipilimumab, an anti-CTLA-4 antibody (6), have
been amongst the first to be approved by the FDA for mainstream
use (although some immunotherapies such as Bacilli Calmette–
Guerin have been used clinically for decades without the fanfare
of the aforementioned therapies). These two therapies, which
provide overall survival benefits in castration-resistant prostate
cancer and melanoma respectively, have generated enthusiasm
and played a central role in re-introducing immunotherapy into
the mainstream. Unfortunately, the benefit imparted by these and
other immune therapies remains modest. Sipuleucel-T provides
no statistical benefit in freedom from progression and improves
median overall survival by about 16 weeks (5). Similarly, ipili-
mumab also provides a survival benefit of roughly 16 weeks (6).
Thus, although these therapies may validate the concept of cancer
immunotherapy and are an important first step, they fall short of
the theorized potential of eradicating metastatic disease. Unfor-
tunately, to date, clinical studies of cancer immunotherapy have
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failed to manifest the pre-clinical and theoretical promise of this
approach. In this manuscript we will review some of the hurdles
of cancer immunotherapy including the need to overcome tumor-
induced immune suppression and immune escape. We will discuss
the importance of inducing antigen-specific immune responses for
successful immunotherapy but also consider the need for antigen
specificity as a major potential pitfall of immunotherapy given
tumor heterogeneity, immune editing, and antigen loss. Finally,
we will discuss how combinatorial strategies may overcome some
of the pitfalls of antigen specificity and highlight recent studies
from our lab which suggest that the induction of antigen non-
specific immune responses may also produce robust anti-tumor
effects and bypass the need for antigen specificity.
SHORT-COMINGS OF CANCER IMMUNOTHERAPY
A recent publication summarizing results from the Society for
Immunotherapy of Cancer (SITC) immunotherapy summit iden-
tifies nine critical hurdles in cancer immunotherapy (7). Of these
nine critical hurdles, eight are related to the development of thera-
peutics and one is inherent to the therapies or diseases themselves.
This one: the “complexity of cancer, tumor heterogeneity, and
immune escape” encompasses a huge and diverse range of biolog-
ical issues. Below we will consider some of these critical hurdles as
well as other potentially critical obstacles.
One obstacle recently described by Lesterhuis and colleagues
is that the timing and dosing for many immunotherapy regi-
mens is often empirically derived and further refinement of these
technical aspects may improve outcomes (8). In many ways this
obstacle is directly attributable to the “limited funds available to
translate science into patients.” The timing and dosing of many
immunotherapy regimens tested in the clinic are extrapolated
from pre-clinical regimens or from phase I trials assessing therapy
tolerability and safety. Although the common thought with cyto-
toxic therapies is that the more that can be delivered, the greater
the anti-tumor effect, this rationale may not hold true when trying
to alter the delicate balance of the immune system for therapeutic
gain. Issues such as exhaustion of effector cells and induction of
suppressive networks must be considered.
Another critical hurdle is the “limitation of current animal
models to predict the efficacy of cancer immunotherapy strategies
in humans.” A recent publication has suggested, based on dis-
cordant gene expression profiles after traumatic or inflammatory
insults, that mice provide poor models of human inflammatory
diseases (9). It should be noted that a single mouse strain was used
to draw such broad conclusions. Although this article has recently
generated attention in the lay media, its conclusions regarding
the short-comings of mouse models have long been recognized
by most researchers. Despite these short-comings, mouse models
remain a staple of pre-clinical studies due to the complex mecha-
nistic studies which can be performed, low cost, and short gener-
ation times amongst numerous other advantages. These authors,
while acknowledging the many limitations of mouse models, do
not endorse abandoning a model which has over many decades
proven its utility in improving the understanding and treatment
of human disease. Care must be taken, however, to make our
pre-clinical models as robust and accurate as possible and to
properly validate pre-clinical findings prior to clinical translation.
Most mouse cancer studies are performed in young mice, however
human cancers most commonly occurs in the aged and the use of
aged mice would be more appropriate for cancer studies. This is
particularly relevant for immunotherapy studies given the signifi-
cant changes in immune functioning with age. In a series of studies
examining immunotherapy in young versus aged mice we have
demonstrated a significant impact of age on efficacy and toxicity
(submitted). We suggest use of aged mice should be considered as
part of the pre-clinical development of any cancer study. We also
suggest that companion animals with spontaneous tumors pro-
vide an excellent platform for validating pre-clinical studies prior
to human translation.
Two other critical hurdles which we will consider together
are “lack of definitive biomarkers for assessment of clinical effi-
cacy of cancer immunotherapies” and that “conventional clini-
cal response criteria do not take into consideration differences
between response patterns to cytotoxic agents and immunother-
apies.” Currently there is no reliable measure of treatment effects
other than survival and imaging responses which makes it difficult
to identify treatments that may have a small but important effect
which needs to be further explored. The lack of validated assays
that can measure immune response across trials make it difficult
to determine how strategies should be altered to improve efficacy.
These issues need to be explored at the pre-clinical level but also as
correlative studies in clinical trials. Unfortunately, the capabilities
of human immune monitoring fall short of the sophisticated assays
used in pre-clinical models and further refinement and develop-
ment are required (10). In many human trials immune monitoring
correlatives consist of a simple characterization of various mark-
ers in the peripheral blood. Mouse (11) and human (12) studies
demonstrate that the immune response observed systemically may
not be representative of what is occurring in the suppressed tumor
microenvironment and draining lymph nodes. Obviously, the eth-
ical issues with justifying repeated biopsy of tumor or draining
lymph nodes make this a dilemma, which is not easily resolved.
An issue not identified by the SITC summit is that clinical
cancer trials of new agents are typically undertaken in patients
with widely metastatic disease who, due to the large burden of
disease, the immunosuppressive activities of the tumor itself, or
the immunosuppressive effects of prior therapies, are unable to
respond to even a very effective immunotherapy. Ohashi and col-
leagues have shown that anti-tumor vaccination is most effective
after surgical de-bulking of the primary tumor (13) demonstrating
that an effective immunotherapy alone may be unable to induce
a clinically significant response if tumor doubling time is short or
tumor burden is high. Not surprisingly, some of the greatest suc-
cesses of immunotherapy have been produced in pre-invasive or
very early stage cancers where there is a limited volume of disease
and patients have received minimal prior therapy. For example,
intravesicular Bacille Calmette–Guerin is a standard of care in the
management of non-muscle invasive bladder cancer demonstrat-
ing superiority to chemotherapy in this setting (14) and an HPV
peptide vaccine demonstrated a 50% complete response rate in
women with pre-invasive vulvar neoplasia (15).
Another limitation of immunotherapy is the potential toxicity
associated with many treatments. As we iatrogenically upset the
delicate balance of the immune system we introduce the potential
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for severe adverse effects. Some therapies can produce systemic
inflammation and cytokine storm with disastrous effects. The sys-
temic administration interleukin (IL)-2 has demonstrated activity
against metastatic renal cell carcinoma and melanoma capable
of producing durable responses in patients with metastatic dis-
ease, but toxicities can be so extreme that it limits its regular
use and treatments are often provided in intensive care units. In
order to limit toxicity and mortality, such treatments are gen-
erally only undertaken at centers with expertise in IL-2 therapy
but access to such centers is limited. Therapy can induce a severe
vascular leak syndrome that emulates sepsis and is character-
ized by hypotension, vasodilation, pulmonary edema, neutrophil
dysfunction, and, without intervention, culminates in end-organ
failure and death (16, 17). In addition to a systemic inflammation
and cytokine storm, another concern with immunotherapy is the
induction of immune responses which inappropriately target self
or through bystander effects damage self tissues. This autoimmu-
nity is seen in certain instances in patients treated with ipilimumab,
where therapy disrupts the immune suppressive mechanism net-
work that prevents anti-cancer immune responses but also use-
fully prevents inappropriate immune responses. Disruption of
the latter can produce autoimmune colitis, dermatitis, hepatitis,
endocrinopathy, and other adverse effects (18). A report by Mor-
gan et al. (19) illustrates the potentially disastrous effects of dis-
rupting immune balance. T-Cells modified with chimeric antigen
receptors (CARs) to HER-2/neu were transferred to a patient with
refractory metastatic colorectal adenocarcinoma. Unfortunately,
this patient suffered fatal pulmonary failure as the transfused T-
cells unexpectedly recognized low levels of the HER-2/neu antigen
present on lung epithelial cells. The adverse effects observed within
this recent trial highlights the critical need to assess the short-
comings of our pre-clinical models as a means to better foreshadow
toxicity responses within the clinic.
Of the hurdles identified by SITC the “complexity of cancer,
tumor heterogeneity, and immune escape” is the only one that
addresses the nature of the disease itself. Under the umbrella of
this one category fall a broad number of biological issues that are
the subject of intense scientific investigation and will ultimately,
more so than any of the other hurdles listed above, dictate the util-
ity of anti-cancer immunotherapy. The“complexity of cancer”and
“tumor heterogeneity” have been recognized for decades in mouse
models. Fidler et al. demonstrated great variability in the metasta-
tic potential of clones from a parent culture of murine melanoma
(20). More recently, a genetic analysis of human renal cell cancers
likewise demonstrated similar variability (21). Taking multiple
spatially distinct biopsies from a single tumor the authors were able
to demonstrate significant genetic changes within a given tumor
providing evidence of the heterogeneity of even a single tumor.
This topic and these studies will be considered in further detail later
in this review. “Immune escape” can refer to a broad spectrum of
mechanisms whereby an anti-tumor immune response is evaded
or subverted. Two widely investigated phenomena that must be
considered under this topic are immunoediting/antigen loss and
tumor-induced immune suppression (Figure 1). Immunoediting
is discussed in a separate section below and we will discuss the
concept of tumor-induced immune suppression here (22, 23).
The hostile nature of the tumor microenvironment and numerous
mechanisms underlying this are well documented. The immune
system is in a delicate balance of fluxes of activation and suppres-
sion that allow for appropriate responses but guard against poten-
tially harmful responses that are inappropriate either in scale or
target. A spectrum of suppressive cells, such as immature dendritic
cells, regulatory T (Treg)-cells, myeloid-derived suppressor cells,
and tumor-associated macrophages, are actively recruited to or
generated within the tumor microenvironment (Figure 1). Like-
wise, a mélange of suppressive cytokines and enzymes, secreted by
the tumor itself or resulting from the chronic inflammation asso-
ciated with many tumors, contributes to the recruitment of the
suppressive cells listed above and to direct suppression of effector
cells. Cytokines such as TGF-beta, IL-10, and prostaglandin (PG)-
E2 with documented immune suppressive effects may be highly
expressed (24). Enzymes such as indolamine-2,3-dioxygenase
(IDO) and arginase, which catabolize tryptophan and arginine
respectively, can create a microenvironment in which immune
effectors cannot activate or proliferate and suppressive cells thrive
(25, 26). They function to both deplete the aforementioned amino
acids essential for effector cell activity but also produce catabo-
lites which can be independently suppressive and can alter the
phenotype of immune cells from activating to suppressive (25, 26).
IMPORTANCE OF ANTIGEN-SPECIFIC RESPONSES
The potential of cancer immunotherapy lies in the ability of the
immune system to specifically distinguish and target non-self from
self. Drawing on Erlichs earlier hypothesis, in the 1960s McFar-
lane Burnet and Lewis Thomas formally proposed the concept
of immune surveillance as the true evolutionary purpose of the
allograft tissue rejection response (27–29). They hypothesized
that given the frequency of somatic mutations and that a pro-
portion of these mutations will give rise to cells with malignant
potential, then there must exist an evolutionary mechanism, likely
immunological in nature, to deal with these potentially dangerous
cells. This implies that tumors, although derived from host tissues
must have some unique property whereby they can be distin-
guished from self. This concept of tumor antigens was confirmed
in experimental animal models by Old and Boyse in the 1960s
(2) who demonstrated the existence of tumor-specific antigens
in murine leukemias and mammary tumors. These findings were
later validated in human melanomas with the discovery of tumor-
infiltrating lymphocytes able to recognize tumor antigens and lyse
malignant cells (30). These findings have since been corroborated
in various malignancies (31). The concept of tumor antigens has
since evolved from tumor-specific antigens to tumor-associated
antigens. These include inappropriately or over-expressed tissue
antigens (i.e., Her-2/neu), viral oncogenes (i.e., v-src), idiotypic
antigens (i.e., B-cell receptor), oncofetal antigens (i.e., CEA),
fusion proteins (i.e., BCR-Abl), and post-translationally modified
glycoproteins (i.e., MUC-1).
To date, the focal point of cancer immunotherapy research
has been T-cell biology and by default tumor antigen-specific
immune responses. A number of these therapies are being tested
for clinical efficacy. As mentioned above, sipuleucel-T (Provenge),
a pulsed dendritic cell vaccine, uses the prostatic acid phosphatase
antigen, although the precise mechanism of its clinical benefit
remains uncertain. Another strategy being tested is the use of
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FIGURE 1 | Immunosuppressive tumor microenvironment and antigen
loss mediate tumor escape. During the elimination phase immune effector
cells such as CTL’s and NK cells with the help of dendritic and CD4+T-cells are
able to recognize and eliminate tumor cells. This killing relies on stress ligands
such as NKG2D and recognition of TAA’s in the TCR-MHC complex. As a result
of tumor heterogeneity, tumor cells which are less immunogenic or have
up-regulated immunosuppressive factors are selected for. These cells are able
to subvert the immune response and escape immune surveillance. Tumor
cells can secrete cytokines that recruit suppressive cells such as regulatory T
(Treg) cells, immature myeloid cells [including immature dendritic cells (iDC)
and myeloid-derived suppressor cells (MDSC)], and M2 macrophages. iDC can
cause T-cell anergy due to lack of co-stimulatory molecules. M2 macrophages
and MDSC inhibit T-cell responses through a variety of mechanisms, including
nutrient sequestration via arginase, reactive oxygen species (ROS) generation,
nitric oxide (NO), as well as interference with trafficking into the tumor site.
Immunosuppressive cytokines and the up-regulation of immunosuppressive
enzymes [like indolamine-2,3-dioxygenase (IDO) and arginase] that catabolize
essential nutrients required for effector cell activation and also produce
immunosuppressive catabolites, contribute to a microenvironment where
immune responses are difficult to instigate and sustain. Furthermore tumor
cells will down-regulate MHC molecules, loose expression of antigenic
molecules, and up-regulate inhibitory molecules such as PD-L1.
CARs that engineer T-cells with receptors specific for target spe-
cific tumor antigens. Two clinical trials have demonstrated the
potential of this approach. Infusion of T-cells with CARs targeting
the CD19 B-cell antigen in chronic lymphoid leukemia (32) or the
NY-ESO-1 antigen in synovial cell sarcoma and melanoma (33)
has demonstrated the ability to induce tumor regression. It has
been implicated that even therapies that are not necessarily billed
as antigen-specific ultimately rely on the generation of antigen-
specific T-cell responses for clinical effect. For example, clinical
studies of CTLA-4 blockade with ipilimumab, which is aimed at
reversing immune suppression, correlate clinical effect with the
generation of T-cells specific to the NY-ESO-1 (34) and Melan-
A (35) antigens. Similarly, Fong and colleagues demonstrate that
clinical response of prostate cancer patients to ipilimumab is also
correlated with the robustness of antigen-specific antibody and
T-cell responses (36).
Given the existence of tumor antigens and their central impor-
tance in anti-cancer immunotherapy an approach being explored
is the use of antigen-specific cancer vaccines. Unfortunately, these
vaccinations, although successful in generating an antigen-specific
immune response, have failed to produce meaningful clinical
responses. For example, as announced by Therion Corporation by
press release in 2006,a phase III trial of the viral PANVAC™ vaccine
in pancreatic cancer patients elicited immune responses to the
CEA antigen in about 70% of patients but without a survival ben-
efit (http://www.prnewswire.com/news-releases/therion-reports-
results-of-phase-3-panvac-vf-trial-and-announces-plans-for-com
pany-sale-56997582.html). Moreover, Canvaxin™ – a melanoma
vaccine – was able to induce antigen-specific responses to the gly-
coprotein tumor-associated antigen TA-90 (37), but Phase III trials
were terminated early due to an observed survival detriment.
IMMUNOEDITING AND IMMUNE ESCAPE SUBVERT
ANTIGEN-SPECIFIC T-CELL RESPONSES
One potential shortcoming of cancer immunotherapy not detailed
above is the need for antigen-specific immune responses. Despite
the findings chronicled above demonstrating the promise and
importance of antigen-specific immune responses in cancer
immunotherapy, many problems exist with this approach. One
issue is the lack of clear target antigens for many tumors. Can-
cer arises from “self” tissues and thus the majority of antigens
expressed have gained central tolerance. Few tumor-specific or
tumor-associated antigens which can uniquely target malignant
cells exist and those which do tend to be poorly immunogenic.
This is in direct contrast to microbes that express a vast array of
proteins, lipids, and carbohydrates which are foreign and strongly
immunogenic. Nonetheless, some tumor antigens do exist and as
demonstrated above immunity against them can be generated.
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The studies above also outline that even when a target antigen is
identified and a response is generated, it may fail to translate into
clinical benefit.
Although the reason for these findings is likely multi-factorial
one of the most plausible explanations is that of immunoedit-
ing and antigen loss (Figure 1). As described by Schreiber and
associates, this concept takes the principles of evolution and nat-
ural selection and applies them on a microscopic scale. It suggests
that during carcinogenesis, tumors which become clinically rele-
vant – under selective pressure by the host immune system – must
have sub-populations which can survive immune pressure and are
thereby selected for as the tumor evolves strategies to evade the
host immune response (38). They describe three processes: the
first is elimination during which active immune surveillance finds
and eradicates the majority of tumor cells (or all of the tumor cells
when it is successful). As a tumor grows and invades surrounding
tissues the release of inflammatory cytokines recruit components
of the innate immune system which will in turn, via cytokines
and in the draining lymph nodes, recruit an adaptive immune
response. The second is dynamic equilibrium during which time
the rapidly dividing and mutating tumor is being eliminated by
the immune system that is simultaneously placing an evolutionary
pressure on the tumor and selecting out variants which by virtue
of poor immunogenicity or other mechanisms are able to survive
the immune attack. In the third phase, escape, tumor subclones
which are poorly recognized or eliminated by the immune system
are able to grow unchecked and become clinically observable dis-
ease. Experimental evidence from this same group demonstrates
that tumors generated under selective immune pressure are less
immunogenic (39). They find that chemically induced sarcomas
from wild-type or RAG 2−/− grow equally well when transplanted
into naïve RAG 2−/− mice but when transplanted into immuno-
competent naïve wild-type mice less than half of the tumors gen-
erated in RAG 2−/− grow as compared to 100% of those generated
in wild-type mice. If tumors can become less immunogenic during
carcinogenesis due to selective pressure from the immune system
then it stands to reason that once established they can also evolve
less immunogenic phenotypes if exposed to a new selective pres-
sure from the immune system, as would occur with immunother-
apy. Clinically, this concept is confirmed by the loss of the MART-1
antigen in melanoma patients after adoptive transfer of MART-1
specific T-cells (40, 41). In addition to antigen loss, there is evi-
dence that tumor cells also down regulate the ability to present
antigen, either by down-regulating major histocompatibility com-
plex (MHC) or antigen processing capabilities (42, 43). Also sup-
porting this hypothesis, it has been demonstrated that the patients
who respond to antigen-specific therapies, such as a MUC-1 pep-
tide pulsed dendritic cell vaccine, are those who have epitope
spreading where an immune response is generated against tumor
antigens not targeted by the antigen-specific therapy (44). This
may be one mechanism whereby antigen-specific therapies can
overcome this shortcoming and it may be that only those patients
who are able to overcome the outgrowth of tumor subclones which
poorly express MUC-1 are able to produce a clinically meaningful
response, although this is not conclusively demonstrated.
In this sense, tumor heterogeneity is a major obstacle in that
the tumor subclones which do not express a given antigen or
have some other trait which makes them poorly immunogenic
will be selected for after immunotherapy. Recent genetic studies
demonstrate the complexity of somatic mutations within a single
melanoma (45) and the heterogeneity of spatially distinct biop-
sies from renal cell cancers (21) leading the authors of the latter
to conclude that “intratumor heterogeneity, associated with het-
erogeneous protein function, may foster tumor adaptation and
therapeutic failure through Darwinian selection.” As mentioned
above, part of this process may entail selection of cells which are
poorly immunogenic by virtue of low expression of tumor anti-
gens or dysfunctional antigen-presenting machinery and part of
this process may entail selection of cells which induce, by any num-
ber of mechanisms, an immunosuppressive tumor microenviron-
ment (Figure 1). Antigen-specific effector T-cells appear to be
particularly prone to both of these mechanisms since they rely on
antigen recognition and are also more sensitive to direct suppres-
sion in the microenvironment, given up-regulation of molecules
like PD-1, CTLA-4, Fas, and Lag-3 on antigen-specific activated
T-cells (Figure 2). We propose that this may be an Achilles heel
of many current immunotherapy approaches that limits both the
magnitude and frequency of responses.
ANTIGEN NON-SPECIFIC IMMUNOTHERAPY APPROACHES
There are some therapies that tend to be less susceptible to the
short-comings of the antigen-specific therapies listed above. These
types of therapies can include cytokines such as IL-2, immunos-
timulatory agents such as bacterial DNA, agonists and antago-
nists of key immunoregulatory molecules such as CD40 or PD-1,
inhibitors of key enzymes such as cyclo-oxygenase or IDO, and
vaccine strategies capable of encompassing the broad array and
heterogeneity of tumor antigens such as syngeneic whole cell
vaccines and in situ vaccines. As mentioned above in the discus-
sion of ipilimumab, these therapies also rely, at least in part, on
the generation of antigen-specific responses but we classify them
for the purpose of discussion as antigen non-specific when they
are not specifically targeted to one or a few antigens. They tend
to be multi-modal and can have direct anti-tumor effects, tar-
get the suppressive tumor microenvironment, and activate innate
immunity and adaptive immunity for both antigen-specific and
antigen-non-specific killing (i.e., non-MHC-restricted killing by
natural killer cells, macrophages, and T-cells) with most func-
tioning through parallel mechanisms. For example, inhibition
of cyclo-oxygenase can have direct cytotoxic effects on tumor
cells by depriving them of necessary growth signals or induc-
ing the intracellular accumulation of arachidonic acid (46, 47)
and can also reverse immune suppression by blocking production
of PGE2 (48, 49). Similarly, CpG oligodeoxynucleotides, which
are recognized as bacterial DNA products and signal through
toll-like receptor-9 (50, 51), can function to activate B-cells, den-
dritic cells, natural killer cells, macrophages, and lymphocytes but
can also inhibit immunosuppressive myeloid-derived suppressor
cells (52). Numerous approaches have been developed to target
the immunosuppressive tumor microenvironment. Regulatory T
(Treg)-cells are a well-studied component of tumor-induced sup-
pression and can inhibit the function of effector T-cells and APC
(53). The CD25 molecule (high affinity IL-2 receptor) expressed
on Treg cells is targeted by the antibody daclizumab (Zenapax)
and by the IL-2 diphtheria toxin fusion protein denileukin diftitox
(Ontak).
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FIGURE 2 | Antigen-specific cytotoxicT-lymphocytes and
antigen-non-specific bystanderT-cell killing in an immunogenic and
suppressive tumor microenvironment. T-cells activated via TCR
engagement up-regulate markers, including CD25, CTLA-4, and PD-1.
Antigen-non-specific activated cytotoxic T-cells have a CD25− and NKG2D+
phenotype. In the immunosuppressive environment antigen-non-specific
activated T-cells may be resistant to suppressive signaling via PD-1 or CTLA-4
and may recognize targets expressing NKG2D ligands even when antigen is
lost and MHC is down-regulated whereas antigen-specific T-cells may become
anergic.
Activated T-cells up-regulate expression of the inhibitory
CTLA-4 molecule and it competes with the co-stimulatory mol-
ecule CD28 for binding of B7, acting as a feedback inhibitory
mechanism. This feedback inhibitory mechanism is taken advan-
tage of by tumors that use it to inactivate effector T-cells in the
tumor microenvironment. Blockade of CTLA-4 with ipilimumab
has demonstrated promising clinical results with regression of
melanoma in some patients and a benefit in median overall sur-
vival of 2.1 and 3.6 months in two clinical trials (6, 54). These
findings validate the central role of CTLA-4 in maintaining tumor
immune tolerance and suppressing tumor reactive T-cells.
Another strategy being tested in the clinical trials is inhibi-
tion of the immunosuppressive enzyme IDO. IDO is an inducible
tryptophan-catabolizing enzyme which can function to induce
tolerance to alloantigens as demonstrated by its prevention of T-
cell-mediated fetal rejection in mice (26, 55). A growing body
of evidence suggests that, akin to many other immunoregulatory
mechanisms, IDO is high-jacked by tumors to induce tolerance
and may even act as a master switch coordinating the different
aspects of the suppressive tumor microenvironment. IDO has been
demonstrated to be inappropriately expressed by tumors and can
coordinate the induction of Tregs and inhibition of natural killer
cells and effector T-cells and can be up-regulated to counteract
the effects of cancer immunotherapy (56, 57). The potential of
inhibiting IDO as a means to reverse tumor-induced immune sup-
pression and promote an anti-tumor immune response has been
demonstrated repeatedly in pre-clinical studies and both compet-
itive inhibitors and small molecule inhibitors of this enzyme are
being tested in clinical trials.
Massive expansion, activation, and non-MHC-restricted killing
by NK cells, macrophages, and memory T-cells can be induced by
intense immune-stimulatory therapies such as CD40 agonists, IL-
2, GM-CSF, IL-12, and CpG. The advantage of these approaches is
that they provoke a broad immune response involving many cell
types and are not dependent on a specific antigen. As mentioned
above, CpGs can activate APC such as dendritic cells through toll
receptor-9 signaling (50, 58) causing increased antigen presen-
tation, co-stimulation, and pro-inflammatory cytokine secretion
which can, in turn, trigger innate and adaptive cell-mediated
immunity (51).
Immunotherapy with potent cytokines such as IL-2 or IL-12
can provoke tumor rejection at least partially through a non-
MHC-restricted mechanism that includes NK and T-cells (59–62).
These cells likely identify and lyse target malignant cells by recogni-
tion of NKG2D ligands as opposed to specific antigens. Moreover,
it has been demonstrated that IL-2 can cause conversion of NK
and T-cells to lymphokine-activated killers which also recognize
and kill target cells through an antigen independent mechanism
(63). A recent report demonstrates the ability of a CD40 agonist
to induce tumor regression of pancreatic adenocarcinoma in both
a pre-clinical trial and a human clinical trial (64). The authors
conclude that the anti-tumor effects are mediated by the cytotoxic
effects of macrophages without a dependence on antigen-specific
T-cells. These examples and the innumerable other such stud-
ies demonstrate the potential of this type of therapy to induce
anti-tumor immunity. The advantage, at least in theory, is that
they are not dependent on a specific cell type or antigen but instead
create an environment where an anti-tumor immune response is
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supported and can efficiently recognize and eradicate malignant
cells thus potentially rendering these therapies more resistant to
the immune evasive mechanisms of tumors described above.
ANTIGEN NON-SPECIFIC T-CELL RESPONSES
Classically, T-cells require two signals via the T-cell receptor (TCR)
and a co-stimulatory signal for activation and proliferation, and
the need for a third signal (cytokine secretion) has been described
for cytotoxic effector function of CD8+ T-cells. These require-
ments for activation can, however, be bypassed in a phenomenon
termed “bystander activation.” In the setting of very high cytokine
stimulation, as occurs locally during viral and bacterial infections,
memory T-cells can become activated and proliferate without the
need for antigen-specific TCR engagement (65, 66). The exact
function of these bystander activated T-cells is uncertain but in
light of the up-regulation of cell surface NKG2D it has been sug-
gested that they play a role in viral clearance (67,68). Recently stud-
ies from our lab have demonstrated that bystander activated T-cells
also occur after highly stimulatory systemic immunotherapy regi-
mens (62) in a process that is similar to what is observed after infec-
tions such as influenza. These highly stimulatory immunotherapy
regimens such as CD40 agonist and IL-2, CpG and IL-15, or IL-2
and IL-12 induce marked expansion of CD8+ T-cell compart-
ment that primarily consists of CD44high memory CD8+ T-cells
(62). In murine models, the bystander memory CD8+ T-cells
induced by these therapies proliferate and exhibit effector func-
tions without the need for TCR engagement and produce signifi-
cant anti-tumor effects which are dependent on IFN-g, IL-12, and
Fas ligand expression but independent of CD4+ T-cells, NK cells,
and perforin (69, 70). After immunotherapy (62) these antigen-
non-specific activated memory CD8+ T-cells (AN-CTL) have a
surface marker phenotype that is different than that of antigen-
specifically activated T-cells through TCR engagement (Figure 2).
In contrast to traditionally activated naïve or memory CD8+ T-
cells, these AN-CTLs do not up-regulate surface expression of
CD25 and PD-1 but do express the natural killer cell activating
receptor, NKG2D giving them a unique NKG2D+CD25−CD8+
phenotype. The anti-tumor effects of these cells in vivo appears
to be, in addition to IFN-g, IL-12, and Fas ligand, dependent on
NKG2D as in vivo blockade of NKG2D significantly reduces the
anti-tumor efficacy (62). These AN-CTLs express granzyme B and
are post-therapy the only T-cells with cytolytic activity.
In TCR transgenic OT-1 mice, in which greater than 95% of
the T-cells have TCRs specific for ovalbumin (OVA), vaccination
with OVA produced OT-1 CD8+ T-cells which were able to lyse
OVA-expressing EG7 tumor cells but not the OVA-negative EL4
parental cell line. Conversely, after highly stimulatory systemic
immunotherapy with CD40 agonist and IL-2, bystander activated
antigen non-specific OT-1 CD8+ T-cells are able to lyse both the
OVA-expressing and OVA-negative targets ex vivo demonstrating
their ability to kill without TCR engagement (62). Mirroring these
results, in vivo therapy in OT-1 mice led to significant anti-tumor
effects against OVA-negative 3LL tumors. We observed expansion
of CD8+ T-cells expressing the unique phenotype of up-regulation
of NKG2D and Granzyme B without up-regulation of CD25 or
PD-1. Importantly, it appears a similar mechanism may exist
in humans. Unlike cells activated by TCR engagement, in vitro
IL-2-treated human memory CD8+ T-cells do not up-regulate
PD-1 and CD25 expressing a similar bystander phenotype to
that seen in mice. Furthermore, in melanoma patients, treatment
with the topical toll-like receptor 7 agonist, imiquimod, produces
infiltration of CD8+CD25− T-cells compared to placebo-treated
tumors (62). As a whole, these studies demonstrate that after
highly stimulatory immunotherapy a pool of memory CD8+ T-
cells expands and has effector function which is both independent
of antigen-specific TCR engagement and plays a critical part in the
anti-tumor efficacy of these therapies.
The anti-tumor effects of these AN-CTL have several advan-
tages over traditional anti-tumor cytotoxic T-cells. Given that these
cells are both activated and recognize their targets in an antigen
non-specific manner they are less sensitive to the mitigating effects
of immunoediting, MHC down-regulation, or antigen loss. As
substantiated in the above studies using OT-1 mice bearing non-
OVA-expressing tumors, these cells can exhibit anti-tumor effects
even when a tumor antigen recognized by their TCR is lacking.
Additionally, these cells may be less prone to immune suppres-
sion as the lack of PD-1 surface expression implies that they are
impervious to suppression by PD-1 ligand expression on tumor
cells. Furthermore, since these cells are derived from the mem-
ory compartment, they have presumably been through multiple
rounds of selection (central and peripheral tolerance) and have
shown the ability to recognize foreign antigens thereby deeming
them “safer” to become activated in a non-specific fashion with-
out causing autoimmunity. Clinically, another advantage of being
derived from the memory T-cell compartment, is that memory
T cells increase with age. Since most malignancies occur in an
aged population with limited thymic output and a limited naïve
T-cell compartment, these memory cells provide an attractive pool
for immunotherapy. The disadvantage of this approach is the need
for a cytokine rich environment; because they are lacking in CD25,
the high affinity IL-2 receptor, these cells rely on copious amounts
of cytokine to maintain their activated state which, as discussed
earlier, has the potential to become extremely toxic.
OVERCOMING THE ACHILLES HEEL OF IMMUNOTHERAPY
WITH COMBINATORIAL STRATEGIES
It is likely that any successful immunotherapy strategy will need
to rely to some extent on adaptive immunity, as any sustained
response will need to rely on the development of immunolog-
ical memory. This is demonstrated by the studies cited above
of antigen-specific responses being correlated with outcomes in
patients treated with ipilimumab. To date, the success of antigen-
specific and non-specific strategies used alone have been unre-
markable. Thus to overcome this Achilles heel of antigen-specific
responses, yet still induce sustainable and clinically meaningful
responses, will likely require the employment of combinatorial
strategies using antigen-specific and non-specific approaches. This
idea of targeting numerous mechanisms simultaneously to prevent
the evolution of subclones which can circumvent the therapy has
been highly successful in the management of HIV infection. For
example, antigen-specific CD8 T-cells require TCR engagement
whereas AN-CTLs recognize their targets via NKG2D ligands, thus
the mechanisms of killing may be complimentary and a tumor
would have to evolve strategies to overcome both of these mech-
anisms for immune evasion. Combinatorial strategies may also
avoid some of the pitfalls of antigen-specific therapies and provide
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superior outcomes. As we have previously reviewed, the use anti-
gen non-specific therapies can induce innate immunity and AN-
CTLs that can “de-bulk tumors, increase antigen release, sway
the tumor microenvironment from suppressive to permissive, and
induce a milieu of pro-inflammatory cytokines” all of which serve
to create an environment where antigen-specific therapies can be
more effective (71). The idea that combining an antigen-specific
therapy may be improved by combining with an antigen non-
specific therapy has been demonstrated in a melanoma vaccine
trial (72). Vaccinated patients produced a measurable antigen-
specific T-cell response to the vaccine antigens but these vaccine
primed responses were significantly increased following CTLA-4
blockade with ipilimumab. A similar question is whether these
combinatorial strategies can not only increase the robustness of
the response to the targeted antigens but induce a response against
new tumor antigens. In a clinical trial using nodal injection of CpG
molecules in melanoma patients, a response was generated against
melanoma associated antigens in 50% of the patients suggesting
that this approach could increase the antigens targeted after an
antigen-specific therapy (73). Clinically, there is some data that
these types of combination therapies may be an effective treatment
strategy as the combination of immunomodulatory cytokines
such as GM-CSF or IL-12 with vaccines has shown efficacy in
preliminary trials (74, 75).
CONCLUSION
Over the last decade cancer immunotherapy has evolved from
a marginal idea to a reality in cancer therapy. Staggering break-
throughs are occurring with regularity and promising novel ther-
apies that have the potential to change the paradigm of cancer
treatment are on the horizon. Despite this promise and opti-
mism the clinical efficacy of cancer immunotherapy has been
modest to date. We have outlined above a number of poten-
tial obstacles to improving the effectiveness of immunotherapy.
Chief amongst these is the need to overcome the tumors ability to
evade an effective immune response. We suggest that combination
immunotherapy regimens, working by many mechanisms simul-
taneously, may help address this obstacle. One approach which
may be particularly useful in this regard is the induction of AN-
CTLs which can bypass the need for antigen specificity and thereby
help overcome the Achilles heel of cancer immunotherapy. Under-
standing how best to combine immunotherapy strategies is an area
of active investigation which will further solidify immunotherapy
in the arsenal of cancer therapeutics.
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